Veröffentlichungen Prof. Dr. Hartmann
Publications of Prof. Dr. Hartmann
 Ausgewählte Publikationen bis 1998
Selected publications until 1998

  1. R. W. Hartmann and C. Batzl. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J. Med. Chem. 1986, 29, 1362-1369.

  2. H. Bayer, C. Batzl, R. W. Hartmann, und A. Mannschreck. New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives. J. Med. Chem. 1991, 34, 2685-2691.

  3. R. W. Hartmann, C. Batzl, T. Pongratz, und A. Mannschreck. Synthesis and aromatase inhibition of 3-cycloalkyl-substituted 3-(4-aminophenyl)piperidine-2,6-diones. J. Med. Chem. 1992, 35, 2210-2214.

  4. R. W. Hartmann, H. Bayer, und G. Grün. Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans and tetralins. J. Med. Chem. 1994, 37, 1275-1281.

  5. R. W. Hartmann, H. Bayer, G. Grün, T. Sergejew, U. Bartz, und M. Mitrenga. Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom. J. Med. Chem. 1995, 38, 2103-2111.

  6. G.A. Wächter, R. W. Hartmann, T. Sergejew, G. L. Grün, und D. Ledergerber. Tetrahydro-naphthalenes: Influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17. J. Med. Chem. 1996, 39, 834-841.

  7. V.C.O. Njar, M. Hector, und R. W. Hartmann. 20-Amino- and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17α-hydroxylase/C17,20-lyase (P450 17). Bioorg. Med. Chem. 1996, 4, 1447-1453.

  8. T.F. Sergejew und R. W. Hartmann. Effect of a diphenylethylenediamine platinum complex on steroidogenesis in rats. J. Steroid Biochem. Molec. Biol. 1996, 58, 243-248.

  9. D. Ledergerber, M. Frotscher, und R. W. Hartmann. Novel highly active thromboxane A2 synthase inhibitors void of carboxylic groups. Arch. Pharm. Pharm. Med. Chem. 1997, 330, 3-5.

Publikationen ab 1999
Publications since 1999

  1. Le Borgne, M., Marchand, P., Delovoye-Seiller, B., Robert, J.-M., Robert-Piessard, S., Le Baut G., Hartman R.W., Palzer, M., New selective nonsteroidal aromatase inhibitors: Synthesis and inhibitory activity of 2,3 or 5-( a -azolybenzyl)-1H-indoles, Bioorg. Med. Chem. Lett. 1999, 9, 333-336.

  2. Wachall, B.G., Hector, M., Zhuang, Y., Hartmann, R.W., Imidazole substituted biphenyls - a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer, Bioorg. Med. Chem. 1999, 7, 1913-1924.

  3. Zhuang, Y., Hartmann, R.W., Synthesis and evaluation of azole-substituted 2-aryl-6- methoxy-3,4-dihydronaphthalenes and -naphthalenes as inhibitors of 17 a -hydroxylase- C17,20-lyase (P450 17), Arch. Pharm. Pharm. Med. Chem. 1999, 332, 25-30.

  4. Baston, E., Hartmann, R.W., N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5 a -reductase type I and II inhibitory activity, Bioorg. Med. Chem. Lett. 1999, 9, 1601-1606.

  5. Hartmann, R.W., Frotscher, M., 1-Imidazolylcarbonyloxy-substituted tetrahydroquinolines and pyridines : Synthesis and evaluation of P450 TxA2 inhibition, Arch. Pharm. Pharm. Med. Chem. 1999, 332, 358-362.

  6. Haider, N., Hartmann, R.W., Steinwender, A., Synthesis of 2- [ 2-(1-imidazolyl)ethyl ] -4-phenylcycloalka [ g ] phthalazin-1(2H)-ones as thromboxane A 2 synthase inhibitors, Arch. Pharm. Pharm. Med. Chem. 1999, 332, 408-409.

  7. Zhuang, Y., Wachall, B.G., Hartmann, R.W., Novel imidazolyl and triazolyl substituted biphenyl compounds: Synthesis and evaluation as nonsteroidal inhibitors of human 17 a - hydroxylase-C17,20-lyase(P450 17), Bioorg. Med. Chem., 2000, 8, 1245-1252

  8. Jacobs, C., Frotscher, M., Dannhardt, G., Hartmann, R.W., 1-Imidazolyl (alkyl) substituted di and tetrahydroquinolines and analogs. Synthesis and evaluation of dual inhibitors of P450 TxA 2 and P450 arom, J. Med. Chem. 2000, 43, 1841-1851.

  9. Picard, F., Baston, E., Reichert, W., Hartmann, R.W., Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5 a -reductase type 1 and 2, Bioorg. Med. Chem., 2000, 8, 1479-1487.

  10. Hartmann, R.W., Reichert, M., New nonsteroidal steroid 5 a -reductase inhibitors. Syntheses and structure-activity-studies on carboxamide phenylalkyl-substituted pyridones and piperidones, Arch. Pharm. Pharm. Med. Chem., 2000, 333, 145-153.

  11. Reichert, W., Jose, J., Hartmann, R.W., 5 a -reductase in intact DU145 cells: Evidence for isozyme I and evaluation of novel inhibitors, Arch. Pharm. Pharm. Med. Chem., 2000, 333, 201-204.

  12. Le Borgne, M., Duflos, M., Le Baut, G., Nicholls, P.J., Hartmann R.W., Synthesis and biological evaluation of indole derivatives acting as anti-inflammatory or antitumoraldrugs, Ann. Pharm. Fr., 2000, 58,316-320.

  13. Baston, E., Palusczak, A., Hartmann, R.W., 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: Synthesis and evaluation as inhibitors of steroid 5 a -reductases type 1 and 2, Eur. J. Med. Chem., 2000, 35, 931-940.

  14. Hartmann, R.W., Hector, M., Haidar, S., Ehmer, P., Jose, J., Synthesis and evaluation of novel steroidal oximes as inhibitors of P450 17 (17 a -hydroxylase / C17-20-lyase) and 5 a -reductase 1 and 2, J. Med. Chem., 2000, 43, 4266-4277.

  15. Hartmann, R.W., Hector M., Wachall, B.G., Palusczak, A., Palzer, M., Huch V., Veith, M., Synthesis and evaluation of 17-aliphatic heterocycle substituted steroidal inhibitors of 17 a -hydroxylase / C17,20-lyase (P450 17), J. Med. Chem. 2000, 43, 4437-4445.

  16. Kleber, A., Hartmann, R.W., Jose. J., Development of an improved in vitro model to study the adhesion of tumor cells to the basement membrane, Pharm. Pharmacol. Lett. 2000, 10, 55-58.

  17. Ehmer, P.B., Jose, J., Hartmann, R.W., Development of a simple and rapid assay for the evaluation of inhibitors of human 17 a -hydroxylase-C 17,20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli, J. Steroid Biochem. Mol. Biol., 2000, 75, 57-63.

  18. Reichert, W., Hartmann, R.W., Jose, J., Stable expression of the human 5 a -reductase - isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors, J. Enz. Inhib., 2001, 16, 47-53.

  19. Recanatini, M., Bisi, A., Cavalli, A., Belluti, F., Gobbi, S., Rampa, A., Valenti, P., Palzer, M., Palusczak, A., Hartmann, R.W., A new class of non steroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives, and inhibition of P450 enzymes aromatase and 17 a -hydroxylase/C17,20-lyase, J. Med. Chem., 2001, 44, 672-680.

  20. Reichert, W., Michel, A., Hartmann R.W., Jose, J., Stable expression of human 5 a -re-ductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification, J. Steroid Biochem. Mol. Biol., 2001, 78, 275-284.

  21. Kleber, A., Hartmann, R.W., Jose, J., No effect of thromboxane A 2 on the attachment of tumor cell lines MDA MB 231, DU145, and U937 to the basement membrane in an in-vitro model, J. Cancer Res. Clin. Oncol., 2001, 127, 751-754.

  22. Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Schlemmer, R., Spruß, T., Bernhardt, G., Gust, R., Schönenberger, H., 1-(2,6-Dichloro-4-hydroxyphenyl)-2-phenylethanes - new biological response modifiers for the therapy of breast cancer. Synthesis and evalulation of estrogenic/antiestrogenic properties, Arch. Pharm. Pharm. Med. Chem., 2001, 334, 125-137.

  23. Baston, E., Klein, C.D.P., Grimminger, W., Hebecker, N., Hartmann, R.W., Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type, Anti Cancer Drug Des., 2001, 16, 37-47.

  24. Haidar, S., Klein, C.D.P., Hartmann, R.W., Synthesis and evaluation of steroidal hydro- xamic acids as inhibitors of P450 17 (17 a -hydroxylase/C17-20-lyase), Arch. Pharm. Pharm. Med. Chem., 2001, 334, 138-140.

  25. Hartmann, R. W., CYP-17-Inhibitoren: Steroidomimetika zur Behandlung des Prostata- karzinoms, Pharm. Ztg., 2001, 146, 2285-2289.

  26. Hartmann, R.W., Die rationale Entwicklung eines Hemmstoffs von CYP 17, einem neuartigen Target zur Behandlung des Prostatacarcinoms, Magazin Forschung, UdS, 2001, 2, 2-9.

  27. Lehr,C.-M., Hartmann, R.W., Lenhof, H.-P., Das virtuelle Biolabor, Pharm. Ztg., 2001, 146, 2541-2543.

  28. Haidar, S., Ehmer, P.B., Hartmann, R.W., Novel Steroidal Pyrimidyl Inhibitors of P450 17 (17 a-Hydroxylase/C17-20-Lyase), Arch. Pharm. Pharm. Med. Chem., 2001, 334, 373-374.

  29. Salem, O.I.A., Schulz, T., Hartmann, R.W., Synthesis and biological evaluation of 4-(4- alkyl- and Phenylaminocarbonyl)benzoyl)benzoic acid derivatives as nonsteroidal inhibitors of steroid 5 a -reductase isozymes 1 and 2, Arch. Pharm. Pharm. Med. Chem., 2002, 335, 83-88.

  30. Hartmann, R.W., Ehmer, P. B., Haidar, S., Hector, M., Jose, J., Klein, C.D.P., Seidel, S. B., Serge jew, T., Wachall, B. G., Wächter, G. A., and Zhuang Y., Review: inhibition of CYP 17, A new strategy for the treatment of prostate cancer, Arch. Pharm. Pharm. Med. Chem., 2002, 335, 119-128.

  31. Picard, F., Schulz, T., Hartmann, R.W., 5-Phenyl substituted 1-methyl-2-pyridones and 4'-substituted biphenyl-4-carboxylic acids. Synthesis and evaluation as inhibitors of steroid-5 a -reductase type 1 and 2, Bioorg. Med. Chem., 2002, 10, 437-448.

  32. Ehmer, P.B., Bureik, M., Bernhardt, R., Müller, U., Hartmann, R..W., Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells, J. Steroid Biochem. Mol. Biol., 2002, 81, 173-179.

  33. Picard, F. and Hartmann, R.W., N-substituted 4-(4-carboxyphenoxy)benzamides.Synthesis and evaluation as inhibitors of steroid-5 a -reductase type 1 and 2, J. Enzym. Inhib. Med. Chem., 2002, 17, 187-196.

  34. Picard, F., Barassin S., Mokhtarian, A., Hartmann, R.W., Synthesis and evaluation of 2’-substituted 4-(4’-carboxy- or 4’-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and In Vivo active steroid 5 a -reductase type 2 inhibitors, J. Med. Chem., 2002, 45, 3406-3417.

  35. Haidar, S. and Hartmann, R.W., C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17 a -hydroxylase-C17,20-lyase: synthesis and biological evaluation, Arch. Pharm. Pharm. Med. Chem., 2002, 335, 526-534.

  36. Baston, E., Salem, O.I.A. and Hartmann, R. W., 6-substituted 3,4-Dihydro-naphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5 a reductase inhibitors, J. Enz. Inhib. Med. Chem., 2002, 17, 303-320.

  37. Mathur, S., Hassel, M., Steiner, F., Hollemayer, K., Hartmann, R.W., Development of a new approach for screening combinatorial libraries using MALDI-TOF-MS and HPLC- ESI-MS/MS, J. Biomol. Screening, 2003, 8, 136-148.

  38. Hartmann, R.W., Müller, U., Ehmer, P.B., Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis, Eur. J. Med. Chem., 2003, 38, 363-366.

  39. Baston, E. Salem, O.I.A., Hartmann, R.W., Cyclohex-1-ene carboxylic acids: synthesis and biological evaluation of novel inhibitors of human 5 a reductase, Arch. Pharm. Pharm. Med. Chem., 2003, 336 , 31-38.

  40. Haidar, S., Ehmer P.B., Barassin, S., Batzl-Hartmann, C., Hartmann, R.W., Effects of novel 17 a -hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo, J. Steroid. Biochem. Mol. Biol., 2003, 84, 555-562.

  41. Leroux, F., Hutschenreuter, T., Charrière, C., Scopelliti, R., Hartmann, R.W., N -(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substition?, Helv. Chim. Act., 2003, 86, 2671-2686.

  42. Marchand, P., Le Borgne, M., Palzer, M., Le Baut, G., Hartmann R.W., Preparation and pharmacological profile of 7-( a -Azolylbenzyl)-1H-Indoles and indolines as new aromatase inhibitors, Bioorg. Med. Chem. Lett., 2003, 13, 1553-1555.

  43. Aboul-Enein, H.Y., Hefnawy M.M., Ehmer, P.B., Hartmann, R.W., Enantiomeric resolution of some human aldosterone synthase [ CYP 11 B2 ] inhibitors on derivatized polysaccharide chiral stationary phases, J. Sep. Sci., 2003, 26, 1455-1458.

  44. Clement, O.O., Freeman, C.M., Hartmann, R.W., Palusczak A., Handratta, V.D., Vasaitis, T.S., Brodie, A.M.H., Njar, V.C.O., Three Dimensional Pharmacophore Modeling of Human CYP17 inhibitors: Potential Agents for Prostate Cancer Therapy, J. Med. Chem., 2003, 46, 2345-2351.

  45. Hutschenreuter, T.U., Ehmer, P.B., Hartmann, R.W., Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme, J. Enz. Inhib. Med. Chem., 2004, 19, 17-32

  46. Aboul-Enein, H.Y., Kladna, A., Kruk, I., Lichszteld, K., Marchlewicz, M., Michalska, T., Salem, O.I.A., Hartmann, R.W., Prooxidant and antioxidant action of 4-(4-phenoxybenzoyl)benzoic acid derivatives, Biopolymers, 2004, 73, 631-639.

  47. Mathur, S., Picard, F., Dossou, U., Barassin, C., Seidel, S.B., Kang, M.J., Hartmann, R.W., Evaluation of cell permeation of a potent 5α-reductase inhibitor using MALDI-TOF MS, J. Enz. Inhib. Med. Chem., 2004, 19, 425-429

  48. Hartmann, R.W., Palusczak, A., Lacan, F., Ricci, G., Ruzziconi, R., CYP 17 and CYP 19 inhibitors. Evaluation of fluorine effects on the inhibiting activity of regioselectively fluorinated 1-(naphthalen-2-ylmethyl)imidazoles, J. Enz. Inhib. Med. Chem., 2004, 19, 145-155.

  49. Neugebauer, A., Klein, C.D.P., Hartmann, R.W., Protein-dynamics of the putative HCV receptorCD81 large extracellular loop, Bioorg. Med. Chem.Lett., 2004, 14, 1765-1769.

  50. Haider, S., Hartmann, R.W., Inhibition of CYP 17, Potential treatment of prostate cancer, Arab J. Pharm. Sci., 2004, 2, 59-76

  51. Gupta, R.B., Jindal, D.P., Jit, B., Narang, G., Palusczak, A., Hartmann, R.W., Synthesis and evaluation of a dimer of 2-(4-pyridylmethyl)-1-indanone as a novel nonsteroidal aromatase inhibitor, Arch. Pharm. Pharm. Med. Chem., 2004, 337, 398-401.

  52. Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Bernhardt, G., Spruß, T., Beckenlehner, K., Koch, M., Krauser, R., Schlemmer, R., Gust, R., Schönenberger, H., [1,2-Bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer – mode of action I: antitumor activity due to the reduction of the endogenous estrogen level, Arch. Pharm. Pharm. Med. Chem., 2004, 337, 335-348.

  53. Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Bernhardt, G., Spruß, T., Beckenlehner, K., Koch, M., Krauser, R., Schlemmer, R., Gust, R., Schönenberger, H., [1,2-Bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer – mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity, Arch. Pharm. Pharm. Med. Chem., 2004, 337, 349-359.

  54. Kang, M.J., Mathur, S., Hartmann, R.W., Quantitative analysis of 5α-reductase inhibitors in DU145 cells using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry, J. Mass Spectrometry, 2004, 39, 762-769.

  55. Hutter, M.C. and Hartmann, R.W., QSAR of Human Steroid 5α-Reductase Inhibitors:
    Where are the differences between isoenzyme type 1 and 2?, QSAR Comb. Sci ., 2004, 23, 406-415.

  56. Lisurek, M., Kang, M.J., Hartmann, R.W., Bernhardt, R., Identification of monohydroxy progesterones produced by CYP106A2 using comparative HPLC and electrospray ionisation collision-induced dissociation mass spectrometry, Biochem. Biophys. Res. Comm., 2004, 319, 677-682.

  57. Voets, M., Müller-Vieira, U., Marchais-Oberwinkler, S., Hartmann, R.W., Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids, Arch. Pharm. Pharm. Med. Chem., 2004, 337, 411-416.

  58. Kang, M.J., Lisurek, M., Bernhardt, R., Hartmann R.W., Use of high-performance liquid chromatography/electrospray ionization collision-induced dissociation mass spectrometry for structural identification of monohydroxylated progesterones, Rapid Comm. in Mass Spec., 2004, 18, 2795-2800

  59. Leonetti, F., Favia, A., Rao, A., Aliano, R., Paluszcak, A., Hartmann, R.W., Carotti, A., Design, synthesis and 3D QSAR of novel potent and selective aromatase inhibitors, J. Med. Chem., 2004, 47, 6792-6803.

  60. Lézé, M.P., Le Borgne, M., Marchand, P., Loquet, D., Kogler, M., Le Baut, G., Palusczak, A., Hartmann, R.W., 2- and 3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors, J. Enz. Inhib. Med. Chem., 2004, 19, 549-557.

  61. Bild, T., Jose, J., Hartmann, R.W., Discovery of inhibitors of the MCF-7 tumor cell adhesion to endothelial cells and investigation on their mode of action, Arch. Pharm. Pharm. Med. Chem., 2004, 337, 687-694.

  62. Mathur, S., Park, J.D., Kim, D.H., Hartmann, R.W., A Method for Screening Enzyme Inhibitors Using Size Exclusion Chromatography and ESI-LC-MS/MS, J. Biomol. Screening, 2005, 10, 30-35.

  63. Ulmschneider, S., Müller-Vieira, U., Mitrenga, M., Hartmann, R.W., Marchais-Oberwinkler, S., Klein, C.D.P., Bureik, M., Bernhardt, R., Antes, I., Lengauer, T., Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imida­zo­lylmethyleneindanes: potent inhibitors of aldosterone synthase, J. Med. Chem., 2005, 48 , 1796-1805.

  64. Haider, S., Hartmann, R.W., Enzyme inhibitor examples for the treatment of prostate tumor. In: Smith, H.J., Simons, C. (Hrsg.) Enzymes and their inhibition: drug development, CRC Press, 2005, 241-253.

  65. Streiber, M., Picard, F., Scherer, C., Seidel, S.B., Hartmann, R.W., Methyl esters of N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acids) as drugs and prodrugs: a new strategy for dual inhibition of 5α-reductase type 1 and type 2, J. Pharm. Sci., 2005, 94, 473-480.

  66. Ulmschneider, S., Müller-Vieira, U., Klein, C.D.P., Antes, I., Lengauer, T., Hartmann, R.W., Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes / -indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase, J. Med. Chem. 2005, 48, 1563-1575, Add. and Corr. J. Med. Chem. 2005, 48, 4489-4490 .

  67. Panter, B., Jose, J., Hartmann, R.W., 5 a -reductase in human embryonic kidney cell line HEK293: evidence for type II enzyme expression and activity, Mol. Cell. Biochem., 2005, 270, 201-208.

  68. Jindal, D.P., Bedi V., Jit, B., Karkra, N., Guleria, S., Gupta, R., Palusczak, A., Hartmann, R.W., Synthesis and study of some new N-substituted imide derivatives as potential anticancer agents, Il Farmaco, 2005, 60, 283-290.

  69. Angotti, M., Hartmann R.W., Kirby, A.J., Simons, C., Nicholls, P.J., Sewell R.D.E., Smith, H.J., Effect of 2-(4-aminophenylmethyl)-6-hydroxy-3,4-dihydronaphthalen-1(2H)-one on all-trans and 13-cis-retinoic acid levels in plasma quantified by high performance liquid chromatography coupled to tandem mass spectrometry, J. Enz. Inhib. Med. Chem. 2005, 20, 219-226.

  70. Müller-Vieira, U., Angotti, M., Hartmann, R.W., The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of aldosterone synthase (CYP11B2) inhibitors and their potential side effects, J. Steroid Biochem. Mol. Biol. 2005, 96, 259-270.

  71. Voets, M., Antes, I., Scherer, C., Müller-Vieira, U., Biemel, K., Barassin, C., Marchais-Oberwinkler, S., Hartmann, R.W., Heteroaryl substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis, J. Med. Chem., 2005, 48, 6632-6642.

  72. Cavalli, A., Bisi, A., Bertucci, C., Rosini, C., Paluszcak, A., Gobbi, S., Giorgio, E., Rampa, A., Belluti, F., Piazzi, L., Valenti, P., Hartmann, R.W., Recanatini, M., Enantioselective nonsteroidal aromatase inhibitors identified through a multi­disciplinary medicinal chemistry approach, J. Med. Chem., 2005, 48, 7282-7289.

  73. Logé, C., Le Borgne, M., Marchand, P., Robert, J.-M., Palzer, M., Hartmann, R.W., Three-dimensional model of cytochrome P450 human aromatase and docking studies in to the active site, J. Enz. Inhib. Med. Chem., 2005, 20, 581-585.

  74. Ulmschneider, S., Negri, M., Voets, M., Hartmann, R.W., Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2), Bioorg. Med. Chem. Lett., 2006, 16, 25-30.

  75. Lézé, M.P., Le Borgne, M., Pinson, P., Palusczak, A., Duflos, M., Le Baut, G., Hartmann, R.W., Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: Potent and selective aromatase inhibitors, Bioorg. Med. Chem. Lett., 2006, 16, 1134-1137.

  76. Salem, O.I.A., Frotscher, M., Scherer, C., Neugebauer, A., Barassin, S., Streiber, M., Maas, R., Hartmann, R.W., Novel 5-Reductase Inhibitors: Synthesis, Structure-Activity Studies and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids, J. Med. Chem., 2006, 49, 748-759.

  77. Voets, M., Antes, I., Scherer, C., Müller-Vieira, U., Biemel, K., Marchais-Oberwinkler, S., Hartmann, R.W., Synthesis and Evaluation of Heteroaryl Substituted Dihydro­naphthalenes and Indenes: Potent and Selective Inhibitors of Aldosterone Synthase (CYP11B2) for the Treatment of Congestive Heart Failure and Myocardial Fibrosis, J. Med. Chem., 2006, 49, 2222 -2231

  78. Schuster, D., Laggner, C., Steindl, T.M., Palusczak, A., Hartmann, R.W., Langer, T.; Pharmacophore modeling and In Silico screening for new P450 19 (Aromatase) Inhibitors, J. Chem. Inf. Model., 2006, 46, 1301-1311.

  79. Görlitzer, K., Bonnekessel, Ch., Jones, P.G., Palusczak, A., Hartmann, R.W., Exemestan-Derivate – Synthese und Prüfung auf Aromatase-Hemmung, Die Pharmazie, 2006, 61, 575-582.

  80. Gobbi, S., Cavalli, A., Rampa, A., Belluti, F., Piazzi, L., Paluszcak, A., Hartmann, R.W., Recanatini, M., Bisi, A., Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme, J. Med. Chem., 2006,  49, 4777-4780

  81. Jazbutyte, V., Hu, K., Kruchten, P., Bey, E., Maier, S., Fritzemeier K.-H., Prelle, K., Hegele-Hartung, C., Hartmann R.W., Neyses, L., Ertl, G., Pelzer, T., Ageing reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female SHR, Hypertension, 2006, 48, 579-586

  82. Engel, M., Hindie, V.,  Lopez-Garcia, L.A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S., Alzari, P.M., Hartmann, R.W., Piiper, A. and Biondi, R.M., Allosteric activation of protein kinase PDK1 with low molecular weight compounds, EMBO J., 2006, 23, 5469-5480

  83. Drăgan, C.A., Hartmann, R.W., Bureik, M., A fission yeast based test system for the determination of IC50 values of anti prostate tumor drugs acting on CYP21, J. Enz. Inhib. Med. Chem., 2006, 21,547-556

  84. Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Spruß, T., Maucher, A., von Angerer, E., Schiller, C.D., Schneider, M.R., Gust, R., Schönenberger, H., Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies, Cancer Res Clin Oncol, 2007, 133, 153-167

  85. Hartmann, R.W., Müller-Vieira, U., Ulmschneider, S., Voets, M., Discovery of potent and selective inhibitors of human aldosterone synthase (CYP11B2) – a new target for the treatment of congestive heart failure and myocardial fibrosis: A review, soon to be submitted

  86. Neugebauer, A. and Hartmann, R.W., Protein-dynamics of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), Bioorg. Med. Chem. Lett., submitted

  87. Scherer, C., Dossou, U., Boettcher, S., Kang, M.J., Seidel, S.B., Hartmann, R.W., A Novel Concept for BPH Therapy by Hybrid Inhibition of 5α-Reductase Type 1 and Type 2: Transport and Stability Studies in Caco-2 and DU145 Cells, Pharm. Res., submitted

  88. Panter, B., Jose, J., Hartmann, R.W., Protein characterisation of human steroid 5α-reductase type II: Impact of posttranslational modification on molecular weight and isoelectric point, Mol. Cell. Biochem., submitted

  89. Boettcher, S., Werth, R., Hartmann, R.W., Immobilized Enzymes for HTS of Chemical Libraries: Studies Applying HPLC-ESI-MS/MS, soon to be submitted

  90. Scherer, C., Streiber, M., Dossou, U., Seidel, S.B., Boettcher, S., Kang, M.J., Hartmann, R.W., Evaluation of a Novel Concept for BPH Therapy by Hybrid Inhibition of 5α-Reductase Type 1 and Type 2 using in Vitro Models, J. Pharm. Sci., submitted

  91. Neugebauer, A., Hartmann R. W., Klein, C.D.P., Identification of Protein-Protein-Interaction Inhibitors by Chemoinformatics and Machine Learning Methods, J. Med. Chem., submitted

  92. Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Spruß, T., Maucher, A., von Angerer, E., Schiller, C.D., Schneider, M.R., Gust, R., Schönenberger, H., Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies, Cancer Res Clin Oncol, 2007, 133, 153-167

  93. Gobbi, S., Cavalli, A., Negri, M., Schewe K., Belluti F., Piazzi L., Hartmann, R. W., Recanatini M., Bisi A., Imidazolylmethylbenzophenones: a novel class of potent and selective aromatase inhibitors, J. Med. Chem., 2007, 50, 3420-3422

  94. McCarthy, A., Hartmann R. W., Abell, A., Evaluation of 4’-Substituted Bicyclic Pyridones as non-steroidal Inhibitors of Steroid 5α-Reductase, Bioorg. Med. Chem. Lett, 2007, 17, 3603-3607

  95. Neugebauer, A., Hartmann, R. W., Klein, C.D.P., Prediciton of Protein-Protein Interaction Inhibitors by Chemoinformatics and Machine Learning Methods, J. Med. Chem., 2007, 19,4665-4668

  96. Le Borgne, M., Marchand, P., Nourrisson, M.R., Loquet, D., Palzer, M., Baston, E., Hartmann, R.W., Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(?-azolylbenzyl)-1H-indoles as selective aromatase inhibitors, J. Enz.Inhib. and Med. Chem., 2007, 22, 667-676

  97. Pinto-Bazurco Mendieta, M. A.E., Negri, M., Jagusch, C., Hille, U.E., Müller-Vieira, U., Schmidt, D., Hansen, K., Hartmann, R.W., Synthesis, biological evaluation and molecular modeling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17, Bioorg. Med. Chem.Lett. , 2008, 18, 267-273

  98. Jagusch, C., Negri, M., Hille, U.E., Hu, Q., Bartels, M., Jahn-Hoffmann, K., Pinto- Bazurco Mendieta M.A.E., Biemel, K., Rodenwaldt, B., Müller-Vieira, U., Schmidt, D., Lauterbach, T., Recanatinti, M., Cavalli, A., Hartmann, R.W., Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α -hydroxylase- 17,20-lyase (CYP17) – Part I:heterocyclic modifications of the core structure, Bioorg. Med. Chem., 2008, 16, 1992-2010

  99. Frotscher, M., Ziegler, E., Marchais-Oberwinkler, S., Kruchten, P., Neugebauer, A., Fetzer, L., Scherer, C., Müller-Vieira, U., Messinger, J., Thole, H., Hartmann, R.W., Design, Synthesis and Biological Evaluation of (Hydroxyphenyl)- naphthalene and quinoline derivatives: Potent, Selective and Non-Steroidal Inhibitors of 17α -Hydroxysteroid Dehydrogenase Type 1 (17α -HSD1) for the Treatment of Estrogen- Dependent Diseases, J. Med. Chem., 2008,51, 2158-2169

  100. Holzer, M., Ziegler, S., Kronenberger, B., Klein, C.D.P., Hartmann, R. W., Microwave assisted syntheses of amino acid ester substituted benzoic acid amides: Potential inhibitors of human CD81-receptor HCV-E2 interaction, The open Medicinal Chemistry Journal, 2008, 2, 21-25

  101. Holzer, M., Ziegler, S., Albrecht, B., Kronenberger B., Bartenschlager R., Kattner, L., Klein, C.D., Hartmann, R. W., Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction, synthesis and structure optimization, Molecules, 2008, 13, 1081-1110

  102. Hartmann, R.W., Müller-Vieira, U., Ulmschneider, S., Voets, M., Discovery of potent and selective inhibitors of human aldosterone synthase (CYP11B2) – a new target for the treatment of congestive heart failure and myocardial fibrosis: A review, In: Medicinal Chemistry: Chemical and Molecular Aspects of Drug Design and Action, Taylor and Francis/ CRC Publishing Company, 2008, 12,165- 175

  103. Bey, E., Marchais-Oberwinkler, Kruchten, P., S., Frotscher, M., Werth, R., Oster, A., Algul, Ö., Neugebauer, A.,, Hartmann, R.W., Design, Synthesis and Biological Evaluation of Bis(hydroxyphenyl) azoles as Potent and Selective Non Steroidal Inhibitors of 17ß-Hydroxysteroid Dehydrogenase Type 1 (17ß-HSD1) for treatment of Estrogen Dependant Diseases, Bioorg. Med Chem, 2008, 16,6423-6435

  104. Holzer, M., Ziegler, S., Neugebauer, A., Kronenberger, B., Klein, C.D.P., Hartmann, R.W., Virtual Screening and Structural Modification of Salicylates: Inhibitors of Human CD81-Receptor HCV-E2 Interaction, Arch. Pharm.Chem.Life Sci., 2008, 341,478-484

  105. Marchais-Oberwinkler, S. , Kruchten, P., Frotscher M., Ziegler, E., Neugebauer, Bhoga, U., Bey, E., Müller-Vieira, U., Messinger, J., Thole, H., Hartmann, R.W., Substituted 6-Phenyl-2-naphthols. Potent and Selective Non-Steroidal Inhibitors of 17ß-Hydroxisteroid Dehydrogenase Type 1 (17 ß-HSD1): Design, Synthesis, Biological Evaluation and Pharmacokinetics, J. Med. Chem, 2008, doi 10.1021/jm800367 publ.on web 07/17/2008

  106. Pinto-Bazurco Mendieta M., Negri, M., Hu, Q., Hille, U., Jagusch, C., Müller-Vieira, U., Jahn-Hoffmann, K., Schmidt, D., Lauterbach, T., Hartmann, R.W., CYP17 inhibitors. Annulations of Additional Rings in Methyleneimidazole Substituted Biphenyls: Synthesis, Biological Evaluation and Modelling, Arch. Pharm.Chem.Life Sci., in press

  107. Hahner, S., Stürmer, A., Fassnacht, M., Hartmann, R.W., Schewe, K., Cochran S., Zink M., Schirbel A., Allolio B., Pleiotropic effects of etomidate in adrenocortical cells – evidence for intraadrenal regulation of steroidogenesis and profileration, MCE, in press

  108. Heim, R., Lucas, S. Grombein, C., Voets, M., Negri, M., R.W. Hartmann, Overcoming Undesirable CYP1A2 Potency of Pyridylnaphthalene Type Aldosterone Synthase Inhibitors: Influence of Heteroaryl Sustitution on Potency and Selectivity ,J. Med. Chem, in press

  109. Pinto-Bazurco Mendieta M., Negri, M., Jagusch, C., Müller-Vieira, U., Lauterbach T., Hartmann, R. W., Synthesis, Biological Evaluation and Molecular Modeling of Abiraterone Analogs: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer, J. Med. Chem, in press

  110. Hu, Q., Negri, M., Jahn-Hoffmann, K., Zhuang,Y., Olgen, S., Bartels, M., Müller- Vieira, U., Schmidt, D., Lauterbach, T., Hartmann, R.W., Synthesis, Biological Evaluation and Molecular Modelling Studies of Methylene Imidazole Substituted Biaryls as Inhibitors of Human 17α -hydroxylase-17, 20-lyase (CYP17) – Part II: Core Rigidification and Influence of Substituents at the Methylene Bridge, Bioorg. Med Chem, in press

  111. Pinto-Bazurco Mendieta M., Negri, M., Jagusch, C., Müller-Vieira, U., Lauterbach T., Hartmann, R. W., Synthesis, biological evaluation and molecular modeling of abiraterone analogs: Novel CYP17 inhibitors for the treatment of prostate cancer, J. Med.Chem., 2008,51, 5009-5018

  112. Lucas, S., Heim, R., Negri, M., Antes, I., Ries, C., Schewe, K., Bisi, A., Gobbi, S., Hartmann, R.W., Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach, J. Med.Chem. ,2008, 51, 6138-6149

  113. Castellano, S., Stefancich, G., Ragno, R., Schewe, K., Santoriello M., Caroli, A., Hartmann, R.W., Sbardella, G., CYP19 (Aromatase): Exploring the scaffold flexibility for novel selective inhibitors, Bioorg. Med.Chem., 2008, 18, 8349-8358.

  114. Pinto-Bazurco Mendieta M., Negri, M., Hu, Q., Hille, U., Jagusch, C., Müller-Vieira, U., Jahn-Hoffmann, K., Schmidt, D., Lauterbach, T., Hartmann, R.W., CYP17 inhibitors. Annulations of additional rings in methyleneimidazole substituted biphenyls: Synthesis, biological evaluation and modelling,  Arch. Pharm.Chem.Life Sci., 2008, 341, 597-609

  115. Léze, M.-P., Palusczak, A., Hartmann, R.W., Le Borge M., Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors, Bioorg. Med.Chem., 2008, 18, 4713- 47

  116. Bey, E., Marchais-Oberwinkler, S., Werth, R., Negri, M., Al-Soud, Y., Kruchten, P., Oster A., Frotscher, M., Birk, B., Hartmann, R.W., Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl)substituted azoles, thiophenes, benzenes and aza-benzenes as potent and selective non-steroidal inhibitors of 17 ß -  hydroxysteroid dehydrogenase type 1 (17ß-HSD1), J.Med.Chem., 2008, 51, 6725-6739

  117. Gaube, F., Wölfl, S., Pusch, L., Werner, U., Kroll, T.C., Schrenk, D., Hartmann R.W., Hamburger M., Effects of Leuzea carthamoides DC. On human breast adenocarcinoma MCF-7 cells determined by gene expression profiling and functional assays, Planta Medica, 2008, 74,1701-1708

  118. Lucas, S., Heim, Ries, C., Schewe, K., Birk B., Hartmann R.W., In vivo active aldosterone synthase inhibitors with improved selectivity: Lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivates, J.Med.Chem., 2008, 51,8077-8087

  119. Marchais-Oberwinkler, S., Frotscher, M., Ziegler, E., Werth, R., Kruchten, P., Messinger, J., Thole, H., Hartmann, R.W., Structure-activity study in the class of 6-(3’-hydroxyphenyl) naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type1 (17beta-HSD1) inhibitors, Mol.Cell.Endocrino., 2009, 301,205-211 

  120. Marchais-Oberwinkler, S., Frotscher, M., Ziegler, E., Werth, R., Kruchten, P., Messinger, J., Thole, H., Hartmann, R.W., Structure-activity study in the class of 6- (3’-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type1 (17beta-HSD1) inhibitors, Mol. Cell. Endocrinol. 2009, 301, 205-211

  121. Kruchten, P., Werth, R., Marchais-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Development of a biological screening system fort the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agens, Mol. Cell. Endocrinol. 2009, 301, 154-157

  122. Al-Soud, Y. A., Bey, E., Oster A., Marchais-Oberwinkler, S.,Werth, R., Kruchten, P., Frotscher, M., Hartmann, R.W., The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta- HSD) type 1 and type 2,  Mol. Cell. Endocrinol. 2009, 301, 212-215

  123. Kruchten, P., Werth, R., Bey, E., Oster, A., Marchais-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells, J. Steroid Biochem. Mol. Biol. 2009, 114, 200-206

  124. Hille, U., Hu Q., Bartels, M., Müller-Vieira, U., Schmidt, D., Lauterbach, T., Hartmann, R.W., Novel CYP17 inhibitors: Synthesis, biological evaluation, structure-  activity relationships and modelling of methoxy-and hydroxy-substituted methyleneimidazolyl biphenyls, Eur. J. Med. Chem. 2009, 44, 2765-2775

  125. Ries, C., Lucas, S., Heim, R., Birk, B., Hartmann, R.W., Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo, J. Steroid Biochem. Mol. Biol. 2009, 116, 121-126

  126. Stroba, A., Schaeffer, F., Hindie, V., Lopez-Garcia, L., Adrian, I.,  Fröhner, W., Hartmann, R.W., Biondi, R.M., Engel, M., 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: Structure-activity relationships and       thermodynamic characterisation of binding as paradigms for PIF-binding pocket-      targeting compounds, J. Med. Chem. 2009, 15, 4683-4693.

  127. Ziegler, S., Kronenberger B., Albrecht B. A.-M., Kaul A., Gamer A.-L., Klein, C.D., Hartmann, R.W., Development and evaluation of a FACS-based medium throughput assay for HCV entry inhibitors, J. Biomol. Screening 2009, 6, 620-626

  128. Kruchten, P., Werth, R., Marchais-Oberwinkler, S., Bey, E., Ziegler E., Oster A. Frotscher, M., Hartmann, R.W., Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations, Comptes Rendus Chimie 2009, 12, 1110-1116  

  129. Hille, U., Hu, Q., Pinto-Bazurco Mendieta, M., Bartels, M., Vock, C.A., Lauterbach, T., Hartmann, R.W., Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile, Comptes Rendus Chimie 2009, 12, 1117-1126

  130. Bey, E., Marchais-Oberwinkler, S., Negri, M., Kruchten, P., Oster A., Klein, T., Spadaro. A., Werth, R., Frotscher, M., Birk, B., Hartmann, R.W., New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and benzenes: Influence of additional substituents on 17 ß-hydroxysteroid dehydrogenase type 1 (17ß-HSD1) inhibitory activity and selectivity, J. Med. Chem. 2009, 52, 6724-6743

  131. Hu, Q., Negri, M., Olgen, S., Hartmann, R.W., The role of fluorine Substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma, ChemMedChem 2010, 5, 899-910

  132. Oster, A., Klein, T., Werth, R., Kruchten, P., Bey, E., Negri, M., Marchais- Oberwinkler, S., Frotscher, M., Hartmann, R.W., Novel estrone mimetics with high 17β-HSD1 inhibitory activity, Bioorg. Med. Chem. 2010, 18, 3494-3505

  133. Haller, F., Moman, E., Hartmann, R.W., Adamski, J., Mindnich, R., Molecular framework of steroid/retinoid discrimination in 17beta-hydroxysteroid dehydrogenase type 1 and photoreceptor-associated retinol dehydrogenase, J. Mol. Biol. 2010, 399, 255-267

  134. Bansal, R. Guleria, S., Ries, C., Hartmann R.W., Synthesis and antineoplastic activity of O-alkylated derivatives of 7-hydroximinoandrost-5-ene steroids, Arch. Pharm. Chem. Life Sci. 2010, 343, 377-383

  135. Negri, M., Recanatini, M., Hartmann, R.W., Insights in 17β-HSD1 enzyme kinetics and ligand binding by fynamic motion investigation, PloS One 2010, 5, e12026

  136. Welker, M.-W., Von Wagner, M., Ochs, D. Zimmer, V., Hofmann, W.P., Piiper, A., Hartmann, R.W., Herrmann, E., Zeuzem, S., Kronenberger, B., Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C, Digestive and Liver Disease 2010, 42, 735-740

  137. Hu, Q., Jagusch, C., Hille, U., Haupenthal, J., Hartmann, R.W., Replacement of   imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer, J. Med. Chem. 2010, 53, 5749-5758

  138. Gobbi, S., Zimmer, C., Belluti, F., Rampa, A., Hartmann, R.W., Recanatini, M., Bisi, A., Novel highly potent and selective nonsteroidal aromatase inhibitors: Synthesis, biological evaluation and strucure -activity relationships investigation, J. Med. Chem. 2010, 53, 5347-5351

  139. Hu, Q., Yin, L., Jagusch, C., Hille, U.E., Hartmann, R.W., Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors, J. Med. Chem. 2010, 53, 5049-5053

  140. Hahner, S., Stürmer, A., Fassnacht, M., Hartmann, R.W., Schewe, K., Cochran S., Zink M., Schirbel A., Allolio B., Etomidate unmasks intraadrenal regulation of steroidogensis and proliferation in adrenal cortical cell lines, Horm. Metab. Res. 2010, 42, 528-534

  141. Reum, N., Fink-Straube, C., Klein, T., Hartmann, R.W., Lehr, C.-M., Schneider, M., Multilayer coating of gold nanoparticles with drug-polymer coadsorbates, Langmuir 2010, 26, 16901-16908

  142. Oster, A., Hinsberger, S., Werth R., Marchaise-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Bicyclic substituted hydroxyphenylmethanones as novel inhibitors 17β-HSD1 for the treatment of estrogen-dependent diseases, J. Med. Chem. 2010, 53, 8176-8186

  143. Heinzerling, L., Hartmann, R.W., Frotscher, M., Neumann, D., Predicting putative inhibiors of 17β-HSD1, Mol. Inf. 2010, 29, 695-705

  144. Zimmer, C., Hafner, M., Zender, M., Amman, D., Hartmann, R.W., Vock, C.A., N- (pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2), Bioorg. Med. Chem. Lett. 2011, 21, 186-190

  145. Wetzel, M., Marchais-Oberwinkler, S. Hartmann, R.W., 17-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold, Bioorg. Med. Chem. 2011, 19, 807-815

  146. Mohamed, A. H., Ba-Bernardi, L., Burkholz T., Schumann, E., Diesel, B., Zapp, J., Kiemer, A.K., Ries, C.,  Hartmann, R.W., Hosny M., Jacob, C., Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors, NPC 2011, 6, 31-34

  147. Marchais-Oberwinkler, S., Wetzel, M., Ziegler, E., Kruchten, P., Werth, R., Henn, C., Hartmann, R.W., New drug-like hydroxyphenylnaphthol steroidomimetics as potent       and selective 17b-HSD1 inhibitors for the treatment of estrogen-dependent diseases, J. Med. Chem. 2011, 54, 534-547

  148. Hille, U. E., Zimmer, C.,  Vock, C.A., Hartmann, R.W., First selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases, Med. Chem. Lett. 2011, 2,   2-6